Klebsiella Pneumoniae Infections - Pipeline Insight, 2025
Description
DelveInsight’s, Klebsiella Pneumoniae Infections - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Klebsiella Pneumoniae Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Klebsiella Pneumoniae Infections: Overview
Klebsiella pneumoniae is one of a handful of bacteria that are now experiencing a high rate of antibiotic resistance secondary to alterations in the core genome of the organism. Alexander Fleming first discovered resistance to beta-lactam antibiotics in 1929 in gram-negative organisms. Since that time, K. pneumoniae has been well studied and has been shown to produce a beta-lactamase that causes hydrolysis of the beta-lactam ring in antibiotics. Host protection from bacterial invasion mainly depends on two things: polymorphonuclear granulocytes, which phagocytose the bacteria, and serum complement proteins, which are bactericidal. The alternate pathway of complement activation is more active in Klebsiella pneumoniae infection. Neutrophil myeloperoxidase and lipopolysaccharide-binding protein facilitate in defense against Klebsiella pneumoniae infection. To get a Klebsiella infection, a person must be exposed to the bacteria. For example, Klebsiella must enter the respiratory (breathing) tract to cause pneumoniae, or the blood to cause a bloodstream infection.In healthcare settings, Klebsiella bacteria can be spread through person-to-person contact (for example, from patient to patient via the contaminated hands of healthcare personnel, or other persons) or, less commonly, by contamination of the environment. The bacteria are not spread through the air.Patients in healthcare settings also may be exposed to Klebsiella when they are on ventilators (breathing machines), or have intravenous (vein) catheters or wounds (caused by injury or surgery). Unfortunately, these medical tools and conditions may allow Klebsiella to enter the body and cause infection. Klebsiella infections that are not drug-resistant can be treated with antibiotics. Infections caused by KPC-producing bacteria can be difficult to treat because fewer antibiotics are effective against them. In such cases, a microbiology laboratory must run tests to determine which antibiotics will treat the infection. If the healthcare provider prescribes an antibiotic, patients must take it exactly as the healthcare provider instructs. Patients must complete the prescribed course of medication, even if symptoms are gone. If treatment stops too soon, some bacteria may survive and the patient may become re-infected. Patients must wash their hands as often as possible and follow all other hygiene recommendations.
""Klebsiella Pneumoniae Infections - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella Pneumoniae Infections pipeline landscape is provided which includes the disease overview and Klebsiella Pneumoniae Infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella Pneumoniae Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella Pneumoniae Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
VXN-319: Vaxxilon
VXN-319 is a semi-synthetic multivalent vaccine candidate targeting Klebsiella pneumoniae strains. VXN-319 is a carbohydrate based vaccine currently at the lead optimization stage. Vaxxilon estimates it would provide protection against more than 80% of carbapenem resistant strains. Vaxxilon synthesizes the carbohydrates that resemble the sugar coating which surrounds each bacterial cell. The synthetic carbohydrates are then combined with other components to create conjugate vaccines similar to those that have been approved to prevent infections from bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type B.
Further product details are provided in the report……..
Klebsiella Pneumoniae Infections: Therapeutic Assessment
This segment of the report provides insights about the Klebsiella Pneumoniae Infections drugs segregated based on following parameters that define the scope of the report, such as:
Klebsiella Pneumoniae Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella Pneumoniae Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella Pneumoniae Infections drugs.
Klebsiella Pneumoniae Infections Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Klebsiella Pneumoniae Infections: Overview
Klebsiella pneumoniae is one of a handful of bacteria that are now experiencing a high rate of antibiotic resistance secondary to alterations in the core genome of the organism. Alexander Fleming first discovered resistance to beta-lactam antibiotics in 1929 in gram-negative organisms. Since that time, K. pneumoniae has been well studied and has been shown to produce a beta-lactamase that causes hydrolysis of the beta-lactam ring in antibiotics. Host protection from bacterial invasion mainly depends on two things: polymorphonuclear granulocytes, which phagocytose the bacteria, and serum complement proteins, which are bactericidal. The alternate pathway of complement activation is more active in Klebsiella pneumoniae infection. Neutrophil myeloperoxidase and lipopolysaccharide-binding protein facilitate in defense against Klebsiella pneumoniae infection. To get a Klebsiella infection, a person must be exposed to the bacteria. For example, Klebsiella must enter the respiratory (breathing) tract to cause pneumoniae, or the blood to cause a bloodstream infection.In healthcare settings, Klebsiella bacteria can be spread through person-to-person contact (for example, from patient to patient via the contaminated hands of healthcare personnel, or other persons) or, less commonly, by contamination of the environment. The bacteria are not spread through the air.Patients in healthcare settings also may be exposed to Klebsiella when they are on ventilators (breathing machines), or have intravenous (vein) catheters or wounds (caused by injury or surgery). Unfortunately, these medical tools and conditions may allow Klebsiella to enter the body and cause infection. Klebsiella infections that are not drug-resistant can be treated with antibiotics. Infections caused by KPC-producing bacteria can be difficult to treat because fewer antibiotics are effective against them. In such cases, a microbiology laboratory must run tests to determine which antibiotics will treat the infection. If the healthcare provider prescribes an antibiotic, patients must take it exactly as the healthcare provider instructs. Patients must complete the prescribed course of medication, even if symptoms are gone. If treatment stops too soon, some bacteria may survive and the patient may become re-infected. Patients must wash their hands as often as possible and follow all other hygiene recommendations.
""Klebsiella Pneumoniae Infections - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Klebsiella Pneumoniae Infections pipeline landscape is provided which includes the disease overview and Klebsiella Pneumoniae Infections treatment guidelines. The assessment part of the report embraces, in depth Klebsiella Pneumoniae Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Klebsiella Pneumoniae Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Klebsiella Pneumoniae Infections. The therapies under development are focused on novel approaches to treat/improve Klebsiella Pneumoniae Infections.
VXN-319: Vaxxilon
VXN-319 is a semi-synthetic multivalent vaccine candidate targeting Klebsiella pneumoniae strains. VXN-319 is a carbohydrate based vaccine currently at the lead optimization stage. Vaxxilon estimates it would provide protection against more than 80% of carbapenem resistant strains. Vaxxilon synthesizes the carbohydrates that resemble the sugar coating which surrounds each bacterial cell. The synthetic carbohydrates are then combined with other components to create conjugate vaccines similar to those that have been approved to prevent infections from bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type B.
Further product details are provided in the report……..
Klebsiella Pneumoniae Infections: Therapeutic Assessment
This segment of the report provides insights about the Klebsiella Pneumoniae Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Klebsiella Pneumoniae Infections
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Klebsiella Pneumoniae Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Klebsiella Pneumoniae Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Klebsiella Pneumoniae Infections drugs.
Klebsiella Pneumoniae Infections Report Insights
- Klebsiella Pneumoniae Infections Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Klebsiella Pneumoniae Infections drugs?
- How many Klebsiella Pneumoniae Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Klebsiella Pneumoniae Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Klebsiella Pneumoniae Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Klebsiella Pneumoniae Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Nomad Bioscience
- Centivax
- LimmaTech Biologics
- Vaxxilon
- Klebsiella pneumoniae Research Project
- Klebsiella infections research project
- Klebsiella pneumoniae tetravalent bioconjugate vaccine
- VXN 319
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Klebsiella Pneumoniae Infections: Overview
- What is Klebsiella Pneumoniae Infections?
- Types of Klebsiella Pneumoniae Infections
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Klebsiella Pneumoniae Infections– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- Klebsiella pneumoniae tetravalent bioconjugate vaccine: LimmaTech Biologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Discovery)
- Comparative Analysis
- VXN 319: Vaxxilon
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Klebsiella Pneumoniae Infections Key Companies
- Klebsiella Pneumoniae Infections Key Products
- Klebsiella Pneumoniae Infections- Unmet Needs
- Klebsiella Pneumoniae Infections- Market Drivers and Barriers
- Klebsiella Pneumoniae Infections- Future Perspectives and Conclusion
- Klebsiella Pneumoniae Infections Analyst Views
- Klebsiella Pneumoniae Infections Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
